A box containing a 5-minute test for COVID-19 from Abbott Laboratories is pictured during the daily briefing on the novel coronavirus, COVID-19, in the Rose Garden of the White House in Washington, DC, on March 30, 2020.
Mandel Ngan | AFP | Getty Images
Abbott Laboratories shares seesawed in premarket trading Thursday after it posted a 16% drop in quarterly profit partly due to a tax expense and suspended its full-year forecast, citing uncertainty surrounding the coronavirus outbreak.
The medical device company has launched three coronavirus tests in the United States, including a new test that shows if a person has antibodies against the the virus, indicating that they’ve had it in the past and were either asymptomatic or recovered.
Even though there is excitement from President Donald Trump and others that Abbott’s tools could be effective in fighting the outbreak, the company is suspending guidance for the year due to “uncertainties regarding the duration and impact of the coronavirus” as sales in some of its other categories fall.
“First and foremost, I want to thank our employees, our customers, and our suppliers for their extraordinary efforts to maintain supply of our critically important products to the people who need them, around the world,” Abbott President and CEO Robert Ford said in a press release. “It’s an unprecedented time and our colleagues are rising to it in unprecedented ways.”
The company reported first-quarter earnings of 65 cents per share, higher than the 58 cents analysts polled by Refinitiv expected. It generated $7.7 billion in revenue, higher than the $7.3 billion analysts expected.
The stock rose by more than 1% after briefly falling half a percent in premarket trading.
Executives are hosting a conference call with Wall Street analysts at 9 a.m. EDT.
This is a developing story. Please check back for updates.